This trial is active, not recruiting.

Conditions embryonic development, pregnancy, vegf
Treatments 10000 iu urinary hcg, 250 mcg recombinant hcg
Phase phase 3
Sponsor Universitair Ziekenhuis Brussel
Collaborator Merck Serono International SA
Start date August 2005
End date December 2007
Trial size 130 participants
Trial identifier NCT00954265, rec-HCG 002


To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
(Active Comparator)
These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
10000 iu urinary hcg
ovulation triggering
These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
250 mcg recombinant hcg
ovulation triggering

Primary Outcomes

blastulation rate
time frame: on day-5

Secondary Outcomes

pregnancy rates, VEGF levels, OHSS rate
time frame: 14 days after oocyte pick up

Eligibility Criteria

Female participants from 20 years up to 36 years old.

Inclusion Criteria: - FSH<12, - normal sperm,less than 36y, - single blastocyst transfer Exclusion Criteria: - endometriosis stage 3&4, - pco

Additional Information

Official title Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program
Trial information was received from ClinicalTrials.gov and was last updated in December 2009.
Information provided to ClinicalTrials.gov by Universitair Ziekenhuis Brussel.